FiercePharma on Twitter; at INTERPHEX 2009

Arsalan Arif, Fierce Life Sciences publisher for FierceMarketsI have three exciting items to share with FiercePharma readers today:

  • Find us on Twitter - For all you Twitter users out there, you can now follow @FiercePharma, the new 140-character edition of our daily report. Calisha Myers, Tracy Staton, and the entire FiercePharma news team will use Twitter to point our readers to the sources we're following when breaking pharmaceutical industry news happens. We'll also highlight limited special content and bonus links. 

  • INTERPHEX 2009 Coverage - We're excited to be in NYC tomorrow! The Fierce Life Sciences editorial team will produce two types of coverage this year. The first will be done live via Twitter throught the day tomorrow, Tuesday March 17. We'll be your eyes and ears as we report firsthand from the show floor and keynote. Follow @FiercePharma to receive our coverage in real-time. A recap of our time at the show will appear in the newsletter and on our website once INTERPHEX wraps up at the end of this week.

  • FiercePharma has a new publisher - Keenly observant FiercePharma readers may have noticed a change to our masthead earlier this year, and now it's official. I'm happy to announce my new role as Group Publisher, Life Sciences at FierceMarkets. Many of you know me from my years on the Fierce team. My top priority is to continue making FiercePharma the first place you turn for industry news. I'm eager to hear your thoughts on how we can best serve you in that capacity. (And if you're at INTERPHEX tomorrow, follow me via @ArsalanFierce or e-mail me.)

Thanks for being part of the FiercePharma community.  - Arsalan Arif

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.